S&P 500   2,981.46 (+0.52%)
DOW   26,933.32 (+0.54%)
QQQ   192.19 (+0.58%)
FB   186.41 (+1.71%)
MSFT   140.58 (+0.74%)
GOOGL   1,225.81 (+0.66%)
AMZN   1,746.81 (+0.60%)
CGC   19.99 (+5.99%)
NVDA   192.60 (+3.25%)
MU   45.09 (+0.51%)
BABA   173.68 (+1.47%)
GE   8.65 (-0.92%)
TSLA   255.80 (-0.45%)
AMD   30.34 (-0.62%)
T   37.52 (+0.13%)
F   8.88 (+0.57%)
ACB   3.72 (+5.98%)
PRI   121.74 (+0.22%)
NFLX   284.14 (-0.49%)
BAC   29.22 (+0.27%)
GILD   64.76 (+0.39%)
DIS   129.55 (-0.12%)
S&P 500   2,981.46 (+0.52%)
DOW   26,933.32 (+0.54%)
QQQ   192.19 (+0.58%)
FB   186.41 (+1.71%)
MSFT   140.58 (+0.74%)
GOOGL   1,225.81 (+0.66%)
AMZN   1,746.81 (+0.60%)
CGC   19.99 (+5.99%)
NVDA   192.60 (+3.25%)
MU   45.09 (+0.51%)
BABA   173.68 (+1.47%)
GE   8.65 (-0.92%)
TSLA   255.80 (-0.45%)
AMD   30.34 (-0.62%)
T   37.52 (+0.13%)
F   8.88 (+0.57%)
ACB   3.72 (+5.98%)
PRI   121.74 (+0.22%)
NFLX   284.14 (-0.49%)
BAC   29.22 (+0.27%)
GILD   64.76 (+0.39%)
DIS   129.55 (-0.12%)
Log in

Accuray Stock Price, News & Analysis (NASDAQ:ARAY)

$2.65
+0.02 (+0.76 %)
(As of 10/15/2019 09:54 AM ET)
Today's Range
$2.62
Now: $2.65
$2.67
50-Day Range
$2.56
MA: $2.80
$3.15
52-Week Range
$2.35
Now: $2.65
$5.40
Volume8,109 shs
Average Volume517,416 shs
Market Capitalization$235.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$418.79 million
Book Value$0.57 per share

Profitability

Net Income$-16,430,000.00

Miscellaneous

Employees998
Market Cap$235.27 million
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.


Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) announced its earnings results on Thursday, August, 15th. The medical equipment provider reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.05. The medical equipment provider had revenue of $117.42 million for the quarter, compared to the consensus estimate of $116.09 million. Accuray had a negative return on equity of 26.69% and a negative net margin of 3.92%. During the same quarter last year, the business posted ($0.01) EPS. View Accuray's Earnings History.

When is Accuray's next earnings date?

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Accuray.

How can I listen to Accuray's earnings call?

Accuray will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Accuray issued on next quarter's earnings?

Accuray updated its FY 2020 earnings guidance on Thursday, August, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $436.86 million.

What price target have analysts set for ARAY?

3 equities research analysts have issued 1 year price objectives for Accuray's shares. Their predictions range from $3.90 to $4.00. On average, they expect Accuray's share price to reach $3.95 in the next twelve months. This suggests a possible upside of 49.3% from the stock's current price. View Analyst Price Targets for Accuray.

What is the consensus analysts' recommendation for Accuray?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.

Has Accuray been receiving favorable news coverage?

News headlines about ARAY stock have trended very negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accuray earned a coverage optimism score of -3.8 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Accuray.

Are investors shorting Accuray?

Accuray saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,920,000 shares, a drop of 21.3% from the August 30th total of 2,440,000 shares. Based on an average daily trading volume, of 588,200 shares, the short-interest ratio is presently 3.3 days. Currently, 2.2% of the company's stock are sold short. View Accuray's Current Options Chain.

Who are some of Accuray's key competitors?

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Advanced Micro Devices (AMD), Exelixis (EXEL), FireEye (FEYE), Netflix (NFLX), Tesla (TSLA), Cypress Semiconductor (CY) and iRobot (IRBT).

Who are Accuray's key executives?

Accuray's management team includes the folowing people:
  • Mr. Joshua H. Levine, Pres, CEO & Director (Age 61)
  • Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 56)
  • Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 60)
  • Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 46)
  • Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $2.65.

How big of a company is Accuray?

Accuray has a market capitalization of $234.82 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.

What is Accuray's official website?

The official website for Accuray is http://www.accuray.com/.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]


MarketBeat Community Rating for Accuray (NASDAQ ARAY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  576
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel